Tumor suppressors control ULBP2, an innate surface ligand of the lymphocyte immune receptor NKG2D by Heinemann, Anja & Paschen, Annette
© 2012 Landes Bioscience.
Do not distribute.
Tumor suppressors control ULBP2,
an innate surface ligand of the lymphocyte
immune receptor NKG2D
Anja Heinemann and Annette Paschen*
Department of Dermatology; University Hospital Essen; Essen, Germany
Keywords: cancer, NKG2D ligand, ULBP2, miR-34, p53
The activating receptor NKG2D, expressed on different innate and adaptive cytotoxic lymphocytes, has been demon-
strated to play an important role in anti-tumor immunity. Now evidence is provided that tumor suppressors control
expression of its ligand ULBP2 supporting the role of this receptor-ligand system as an innate barrier against tumor
development.
Effective anti-tumor immunity is based
on the concerted action of innate and
adaptive lymphocytes that share expression
of the receptor NKG2D.
1 Upon ligand
binding on malignant cells NKG2D
activates the cytotoxic effector function
of Natural Killer (NK) cells and costimu-
lates T-cell activity that in turn leads to
the rejection of transplanted tumors and
decreases the incidence of spontaneous
tumors as shown in different mouse
models.
1 Despite the importance of
NKG2D in anti-tumor immunity, the
mechanisms that control expression of
its ligands in malignant cells are poorly
understood. In 2005, Gasser et al. demon-
strated that genotoxic agents induce
NKG2D ligand (NKG2DL) expression
in murine and human cells.
2 Based on this
observation, the model of NKG2DL as an
innate barrier against tumor development
emerged which led us to ask for the role
of tumor suppressors in the regulation of
their expression.
Recently, we demonstrated that differ-
ent tumor suppressors control expression
of ULBP2, a human NKG2DL. Studies
on melanoma cell lines revealed that
tumor-suppressive microRNAs (miRNAs)
repress ULBP2 expression. miRNAs are
small non-coding RNAs that regulate
mRNA degradation and/or translation
primarily by binding to the 3'-untranslated
region. We identified members of the
miR-34 family (miR-34a and miR-34c)
as direct regulators of ULBP2 mRNA,
affecting both, its degradation and trans-
lation.
3 This miRNA family is of import-
ance for cellular differentiation and when
ectopically expressed in malignant cells,
induces cell cycle arrest, senescence or
apoptosis, explaining its downregulation
in many different tumor entities.
4,5 How-
ever, some of the melanoma cell lines
tested still contained significant amounts
of miR-34 that inversely correlated with
ULBP2 surface expression. Accordingly,
a decrease of miR-34 levels upregulated
ULBP2 while an increase of miR-34
downregulated ligand expression that
interfered with tumor cell killing by NK
cells, demonstrating the functional signi-
ficance of this regulatory mechanism.
3 As
miR-34 family members have recently
been characterized for their importance
in cellular differentiation, we propose
the following model: high levels of
miR-34 in differentiated tissues interfere
with ULBP2 expression, whereas loss
of miR-34, as it frequently occurs in
cancer, facilitates ULBP2 protein expres-
sion, thereby assisting cytotoxic lym-
phocytes in immune surveillance of
malignant cells.
Interestingly, MIR34A and MIR34B/C
genes are under transcriptional control
of the tumor suppressor p53, a regulator
activated by various cancer-related stresses
including DNA damage.
4 p53 is function-
ally inactive in more than 50% of cancers
and those still containing wild type p53
frequently express elevated levels of
the negative regulator MDM2 that by
ubiquitination leads to p53 degradation.
Different small molecule inhibitors, like
Nutlin-3a and RITA, have been deve-
loped for cancer therapy that disrupt the
MDM2-p53 interaction and induce p53
activation.
6 When we treated p53 wild-
type melanoma cells with Nutlin-3a
expression of miR-34 was increased. This
led to a decrease in ULBP2 levels that
could be counteracted by miR-34 specific
inhibitors. The same negative effect of
Nutlin-3a on ULBP2 was observed also
for HCT116 p53
+/+ colon carcinoma cells
but not for isogenic HCT116 p53
2/2
cells.
3 Thus, Nutlin-3a decreased ULBP2
levels in a p53-dependent manner, which
was due, at least in part, to the increase in
cellular miR-34 levels (Fig.1).
While our data point to p53 as an
indirect negative regulator of ULBP2
expression, recent work by Textor et al.
and Li et al. demonstrated that activation
of p53 by either ectopic overexpression or
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treatment of tumor cells with RITA,
increased ULBP2 levels via direct enhance-
ment of its transcription (Fig.1).
7,8 Thus,
p53 seems to play a dual role in the
regulation of ULBP2 expression and we
assume that the context of p53 activation
determines the outcome. Indeed, it has
been demonstrated that Nutlin-3a pre-
ferentially induces cell cycle arrest while
RITA primarily induces apoptosis in
tumor cells, though both substances dis-
rupt the MDM2-p53 interaction. Further-
more the observation by Gasser et al.
who found the induction of NKG2DL
expression upon DNA damage to be
independent of p53 adds another level
of complexity to the control of ULBP2
expression.
2
So far, the involvement of p53 and
miR-34 in the regulation of ULBP2
expression suggests that this NKG2DL
might be of specific relevance in
anti-tumor immunity. Indeed, our pre-
vious studies demonstrated that ULBP2 is
a marker of exceptional clinical signific-
ance in malignant melanoma.
9 Tumor
cells have been described to shed
NKG2DL by proteolytic cleavage or via
exosomes, which allows them to escape
from NKG2D-mediated immune respon-
ses. Ligand shedding most likely explains
the increased levels of soluble NKG2DL
found in sera of cancer patients.
1 When
measuring patient sera for the presence
of soluble ULBP2 and MICA, another
NKG2DL expressed on melanoma cells,
we detected elevated levels of both
markers.
9,10 Interestingly, by correlating
soluble MICA (sMICA) and sULBP2
levels to the patient disease course, we
found only sULBP2, in contrast to
sMICA, to be a strong predictor of poor
prognosis even in early disease stage. On
the one hand, the association between
high sULBP2 and shortened overall sur-
vival might indeed reflect an immune
escape of the tumor, associated with an
accelerated disease progression. On the
other hand, one cannot exclude that
elevated sULBP2 levels could originate
from an exceptionally strong ligand expres-
sion in a highly progressive dedifferen-
tiated tumor phenotype. If the latter is the
case, then mechanisms that drive ULBP2
expression in such tumors await further
investigation.
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Figure1. Model of the regulation of ULBP2 expression. Tumor suppressors control expression
of the NKG2DL ULBP2 at different levels. The tumor suppressor p53 functions as a direct
transcriptional activator of ULBP2. Furthermore it activates transcription of the MIR34A and MIR34B/
C genes. The miR-34 family members miR-34a and miR-34c directly bind to the 3’ untranslated
region of ULBP2 mRNA thereby repressing its translation and enhancing its degradation.
The balance between both regulatory mechanisms determines the expression level of ULBP2 and
in turn the strength of NKG2D dependent immune responses.
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